Brief: NKGen Bio Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01
28/12/2023 21:25
Dec 28 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH, INC. ANNOUNCES DOSING OF FIRST PATIENT IN
ITS
PHASE 1/2A TRIAL WITH AUTOLOGOUS NK CELL PRODUCT, SNK01, FOR THE
TREATMENT OF MODERATE ALZHEIMER’S DISEASE
* NKGEN BIOTECH INC - PLANNING ON CONDUCTING AN INTERIM DATA
READOUT IN Q3 2024
Source text for Eikon: ID:nGNX3lyfR0
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program